These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28183250)

  • 41. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted therapies in upper gastrointestinal malignancies.
    Azzariti A; Silvestris N
    Curr Med Chem; 2014; 21(8):947. PubMed ID: 23992326
    [No Abstract]   [Full Text] [Related]  

  • 43. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gastrointestinal Stromal Tumors: A Review.
    Asija AP; Mejia AV; Prestipino A; Pillai MV
    Am J Ther; 2016; 23(2):e550-7. PubMed ID: 23942136
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
    Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Precision Medicine in Gastrointestinal Pathology.
    Wang DH; Park JY
    Arch Pathol Lab Med; 2016 May; 140(5):449-60. PubMed ID: 27128302
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors.
    Sanchez-Gastaldo A; Gonzalez-Exposito R; Garcia-Carbonero R
    Target Oncol; 2016 Aug; 11(4):479-87. PubMed ID: 26887374
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autophagy in 5-Fluorouracil Therapy in Gastrointestinal Cancer: Trends and Challenges.
    Tang JC; Feng YL; Liang X; Cai XJ
    Chin Med J (Engl); 2016 Feb; 129(4):456-63. PubMed ID: 26879020
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current status and problems in development of molecular target agents for gastrointestinal malignancy in Japan.
    Boku N
    Jpn J Clin Oncol; 2010 Mar; 40(3):183-7. PubMed ID: 20047861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TGF-β signaling in liver and gastrointestinal cancers.
    Katz LH; Likhter M; Jogunoori W; Belkin M; Ohshiro K; Mishra L
    Cancer Lett; 2016 Sep; 379(2):166-72. PubMed ID: 27039259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].
    Hamard C; Ruppert AM; Lavole A; Rozensztajn N; Antoine M; Cadranel J; Wislez M
    Ann Pathol; 2016 Jan; 36(1):63-72. PubMed ID: 26775573
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exploring the microbiota to better understand gastrointestinal cancers physiology.
    Panebianco C; Potenza A; Andriulli A; Pazienza V
    Clin Chem Lab Med; 2018 Aug; 56(9):1400-1412. PubMed ID: 29630505
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deciphering molecular determinants of chemotherapy in gastrointestinal malignancy using systems biology approaches.
    Lin LL; Huang HC; Juan HF;
    Drug Discov Today; 2014 Sep; 19(9):1402-9. PubMed ID: 24793142
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach.
    Muñoz M; Coveñas R
    Saudi J Gastroenterol; 2016; 22(4):260-8. PubMed ID: 27488320
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.
    Wong MS; Sidik SM; Mahmud R; Stanslas J
    Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review.
    Arnold D; Peinert S; Voigt W; Schmoll HJ
    Oncologist; 2006 Jun; 11(6):602-11. PubMed ID: 16794239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Real Impact of Target Therapy in Breast Cancer Patients: Between Hope and Reality.
    Bordonaro S; Berretta M; Tralongo AC; Clementi S; Stanzione B; Tralongo P
    Curr Cancer Drug Targets; 2018; 18(5):480-498. PubMed ID: 28183251
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms.
    Wu WK; Sung JJ; Lee CW; Yu J; Cho CH
    Cancer Lett; 2010 Sep; 295(1):7-16. PubMed ID: 20381235
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical considerations.
    Abdel-Rahman O
    Tumour Biol; 2015 Jan; 36(1):21-31. PubMed ID: 25394897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.